Why the study?
Does nifedipine monotherapy improve blood pressure and affect renal function in essential hypertensive patients?
Does nifedipine monotherapy improve blood pressure and affect renal function in essential hypertensive patients?
Nifedipine monotherapy effectively lowers blood pressure without adversely affecting long-term renal function, as initial hyperfiltration and hyperperfusion do not persist.
Answers are grounded in this paper and cite their sources.
Nifedipine may support BP control without sustained renal impact in hypertension; leaves open randomized confirmation of long-term outcomes.
Twenty-six essential hypertensive patients were entered into a protocol to assess the blood pressure and renal effects of the dihydropyridine calcium antagonist, nifedipine (30 to 120 mg/d given in divided dosage) administered for twelve weeks. Nifedipine monotherapy effectively lowered blood pressure. Glomerular filtration rate (GFR) and effective renal plasma flow (ERPF) were increased following short-term therapy (four weeks); however, there was no net change in GFR or ERPF (compared to placebo) following long-term therapy (12 weeks). Renal vascular resistance was reduced. The filtration fraction and urinary albumin excretion was unchanged throughout the 12-week protocol. We conclude that nifedipine monotherapy does not adversely effect renal function. Tolerance occurs to the initial renal vasodilator response; hyperfiltration and hyperperfusion do not persist.
No takes yet. Share an insight, caveat, or question.
Reams et al. (1989) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: